ReviewBMJ open2026
Derisking translational research in India through the Indian Council of Medical Research (ICMR) network for phase 1 clinical trials and public-private partnerships.
Review in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importancePhase 1 clinical trials fall at a critical intersection of translational research and drug development. With a high failure rate at this stage, only enterprises capable of substantial risk tolerance and heavy investment can step into translational medicine. Academic and public sector researchers in India often lack expertise in early-phase clinical trials. This, along with a lack of dedicated infrastructure, poses some unique challenges in the early-phase drug development process. In this paper, the authors explore public-private partnership (PPP) models of pharmaceutical innovation and propose the establishment of national clinical trial networks as a solution to derisk the industry by jointly undertaking translational research of innovations addressing public health priorities. OBSERVATIONS: PPPs offer an alternative approach to overcome the challenges associated with early-phase clinical trials. By fostering collaboration between public and private entities, PPPs leverage the strengths of public institutions, which can provide infrastructure, funding and scientific expertise, while private companies contribute their experience in clinical trial management and commercialisation. This is of particular importance in the development of drugs of national health priority. CONCLUSION AND RELEVANCE: PPPs offer a promising strategy to expedite early-phase clinical trials in India by promoting collaboration, diversification and innovation. By acknowledging and mitigating the inherent risks, public and private stakeholders can work together to develop effective and accessible treatments for patients in need.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.